Related Experiment Video

Updated: Apr 6, 2026

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

8.0K

rs2910164 Polymorphism Confers a Decreased Risk for Pulmonary Hypertension by Compromising the Processing of

Haitao Liu1, Mai Chen, Feng Wu

  • 1Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.

Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology
|July 24, 2015
PubMed
Abstract

Insights

The rs2910164 polymorphism is linked to a lower risk of pulmonary hypertension. This association may stem from impaired microRNA-146a (miRNA) processing, affecting cyclooxygenase-2 (COX-2) and prostaglandin I2 (PGI2) production.

Area of Science:

  • Genetics
  • Molecular Biology
  • Cardiovascular Research

Background:

  • Pulmonary hypertension (PH) is a complex disease with significant morbidity and mortality.
  • Genetic factors, including single nucleotide polymorphisms (SNPs), are implicated in PH development.
  • The role of microRNA-146a (miR-146a) and its downstream targets in PH pathogenesis requires further elucidation.

Purpose of the Study:

  • To investigate the association between the rs2910164 polymorphism and the risk of developing pulmonary hypertension.
  • To explore the underlying molecular mechanisms involving miR-146a, cyclooxygenase-2 (COX-2), and prostaglandin I2 (PGI2) in PH.
  • To determine the functional relationship between rs2910164 genotype and miR-146a/COX-2 expression levels.

Main Methods:

  • Case-control study including 281 PH patients and 325 healthy controls.
  • Genotyping of the rs2910164 polymorphism using participant DNA.
  • Analysis of miR-146a and COX-2 mRNA and protein expression in lung tissue samples (n=39) via real-time PCR and Western blot.
  • Functional validation of COX-2 as a miR-146a target in pulmonary smooth muscle cells.

Main Results:

  • The rs2910164 polymorphism showed a significant association with pulmonary hypertension risk after adjusting for confounding factors.
  • Individuals with CC and GC genotypes for rs2910164 exhibited a decreased risk of developing PH.
  • Differential expression of miR-146a and COX-2 was observed across different rs2910164 genotype groups.
  • A significant correlation was found between rs2910164 polymorphism and the levels of COX-2 and PGI2 production.

Conclusions:

  • The rs2910164 CC and GC genotypes are associated with a reduced risk of pulmonary hypertension.
  • This protective effect may be mediated by enhanced miRNA processing, leading to better inhibition of COX-2 and PGI2.
  • The findings highlight the rs2910164 polymorphism as a potential genetic marker for PH susceptibility and provide insights into its molecular underpinnings.

More Related Videos

Hypoxia Alters miRNAs Levels Involved in Non-Mendelian Inheritance of Autism Spectrum Disorder in Mice09:13

Hypoxia Alters miRNAs Levels Involved in Non-Mendelian Inheritance of Autism Spectrum Disorder in Mice

Published on: July 11, 2025

35.1K
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

35.0K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.3K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.7K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
116
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
19.9K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
86